Autolus Therapeutics PLC (AUTL) FinancialsAUTLAutolus Therapeutics PLC

Evaluating the bottom line, Autolus Therapeutics PLC maintains a gross margin of 57.61%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -86.33%, while the net margin is -85.60%. These profitability ratios, combined with a Return on Equity (ROE) of -133.00%, provide a clear picture of how effectively AUTL converts its operational activities into shareholder value.

In the context of the broader market, AUTL competes directly with industry leaders such as AQST and RGNX. With a market capitalization of $572.25M, it holds a significant position in the sector. When comparing efficiency, AUTL's gross margin of 57.61% stands against AQST's 70.93% and RGNX's 99.04%. Such benchmarking helps identify whether Autolus Therapeutics PLC is trading at a premium or discount relative to its financial performance.

Autolus has shown a substantial increase in revenue, with Q2 2026 product sales of $45.69 million compared to $20.92 million in Q2 2025, reflecting a strong market demand. The gross margin has improved significantly to 57.61% in Q2 2026, which is a positive indicator of operational efficiency.